10 completed, 5 terminated, 4 active not recruiting, 3 recruiting. 10 Phase 2, 6 Phase 3, 4 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow Antihistamine: new trials by email Literature Review of Antihistamine trials Research Report on Antihistamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 230 | 2023-05-16 | 2026-10-07 |
| Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients Laronidase, Antihistamine, Antipyretic - Mucopolysaccharidosis Type 1 | Phase 3 | Completed | Cinnagen | 12 | 2022-09-10 | 2024-08-06 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| Histamine as a Molecular Transducer of Adaptation to Exercise Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise - Postexercise Hypotension | Early Phase 1 | Active not recruiting | University of Oregon | 80 | 2021-07-28 | 2026-01-23 |
| Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) Capsaicin, Diphenhydramine, Morphine Chloride - Itch | Not applicable | Completed | Aalborg University | 26 | 2021-01-18 | 2022-01-27 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) Ocrelizumab, Antihistamine, Methylprednisolone - Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 769 | 2020-12-03 | 2026-07-24 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Ocrelizumab, Antihistamine, Methylprednisolone - Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 864 | 2020-11-26 | 2026-09-28 |
| Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer H3B-6545, Antihistamine - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 33 | 2020-09-30 | 2025-10-23 |
| Antihistamines, Amantadine and Evolution of COVID-19 Antihistamine, Amantadine - COVID-19 | Recruiting | Consorci Sanitari de Terrassa | 140660 | 2020-03-01 | 2026-04-03 | |
| Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection Antihistamine, Amantadine, ACEI - COVID19, Influenza Vaccination | Recruiting | Consorci Sanitari de Terrassa | 3000 | 2020-03-01 | 2026-03-25 | |
| Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea Antihistamine, Placebo - Irritable Bowel Syndrome, Dermatographism | Phase 3 | Withdrawn | University of Cincinnati | 2020-02-01 | 2026-09-04 | |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Durvalumab, Vicineum, Acetaminophen - Urinary Bladder Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2018-06-07 | 2026-10-27 |
| Personalized Treatment Algorithms for Difficult-to-treat Asthma Cholecalciferol, antihistamine, Azithromycin - Asthma in Children | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 21 | 2018-03-16 | 2021-08-20 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) Cabazitaxel, Antihistamine, Corticosteroid - Circulating Tumor Cell, Metastatic Prostate Cancer | Phase 2 | Unknown | Erasmus Medical Center | 140 | 2017-02-21 | 2021-08-20 |
| A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) ARC-521 Injection, Placebo, antihistamine - Hepatitis B | Phase 1 | Terminated | Arrowhead Pharmaceuticals | 47 | 2016-06-01 | 2026-01-12 |
| Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Ocrelizumab, Lumbar Puncture, Methyloprednisolone - Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | Genentech, Inc. | 131 | 2016-04-29 | 2024-06-04 |
| Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection ARC-520 Injection, entecavir, tenofovir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 12 | 2016-03-01 | 2026-01-13 |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 79 | 2015-12-01 | 2026-01-13 |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection ARC-520, Placebo, entecavir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 32 | 2015-11-01 | 2026-01-13 |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection ARC-520 Injection, placebo, entecavir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2015-09-01 | 2026-01-13 |
Showing 20 of 25. Sign in to see all of them.
Hepatitis B (5) · COVID-19 (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma in Situ (1) · Endolymphatic Hydrops (1) · Ependymoma (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Familial dermographism (1) · Hepatitis D (1) · Hypersensitivity (1)
Arrowhead Pharmaceuticals (5) · Hoffmann-La Roche (3) · Consorci Sanitari de Terrassa (2) · University of Cincinnati (2) · Aalborg University (1) · Children's Hospital Medical Center, Cincinnati (1) · Cinnagen (1) · Eisai Co., Ltd. (1) · Erasmus Medical Center (1) · Genentech, Inc. (1) · Hamilton Health Sciences Corporation (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Pediatric Brain Tumor Consortium (1)
United States (13) · Germany (7) · China (5) · South Korea (5) · Canada (4) · Spain (4) · Brazil (3) · Denmark (3) · Italy (3) · Switzerland (3) · Turkey (Türkiye) (3) · Argentina (2) · Australia (2) · Belgium (2) · Bulgaria (2)
Ali Rabani, Professor (1) · David Bernstein, MD (1) · Dr. Tasnee Chonmaitree (1) · E. Steve Woodle, MD (1) · Gurjit K Khurana Hershey, MD, PhD (1) · John R Halliwill, PhD (1) · Matthias Karajannis, MD, MS (1) · Raju Chelluri, M.D. (1) · Susan Waserman, MD (1) · Susan Waserman, ME (1) · Theresa Guilbert, MD (1)
PMID 39459868, PMID 42208560, PMID 35123074, PMID 35642432, PMID 39770791, PMID 40508884, PMID 40830667, PMID 41754542, PMID 42376811
2014 (3), 2023 (3), 2015 (2), R01DC002620 (1), UM1CA081457 (1)